ArticleScientific reports2025
Predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer with two step feature selection and ensemble learning.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Prognostic and Diagnostic Significance of Annexin A1 in ypT3 Locally Advanced Rectal Cancer Patients.International journal of molecular sciences · 2026Article
- Toward Robust Machine Learning Models for MALDI-TOF MS: Novel Approaches forJournal of proteome research · 2026Article
- The Multifaceted Role of Annexin A1 in Colorectal Cancer: From Molecular Mechanisms to Predictive and Prognostic Implications.Medical sciences (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Patients with locally advanced rectal cancer (LARC) show substantial individual variability and a pronounced imbalance in response distribution to neoadjuvant chemoradiotherapy (nCRT), posing significant challenges to treatment response prediction. This study aims to identify effective predictive biomarkers and develop an ensemble learning-based prediction model to assess the response of LARC patients to nCRT. A two-step feature selection method was developed to identify predictive biomarkers by deriving stable reversal gene pairs through within-sample relative expression orderings (REOs) from LARC patients undergoing nCRT. Preliminary screening utilized four methods-MDFS, Boruta, MCFS, and VSOLassoBag-to form a candidate feature set. Secondary screening ranked these features by permutation importance, applying Incremental Feature Selection (IFS) with an Extreme Gradient Boosting (XGBoost) to determine final predictive gene pairs. The ensemble model BoostForest, combining boosting and bagging, served as the predictive framework, with SHAP employed for interpretability. Through two-step feature selection, the 32-gene pair signature (32-GPS) was established as the final predictive biomarker. In the test set, the model achieved an area under the precision-recall curve (AUPRC) of 0.983 and an accuracy of 0.988. In the validation cohort, the AUPRC was 0.785, with an accuracy of 0.898, indicating strong model performance. The study further demonstrated that BoostForest achieved superior overall performance compared to Random Forest, Support Vector Machine (SVM), and XGBoost. To evaluate the effectiveness of the 32-GPS, its performance was compared with two alternative feature sets: the lasso-gene pair signature (lasso-GPS), derived through lasso regression, and the 15-shared gene pair signature (15-SGPS), consisting of gene pairs identified by all four feature selection methods. The 32-GPS demonstrated superior performance in both comparisons. The two-step feature selection method identified robust predictive biomarkers, and BoostForest outperformed Random Forest, Support Vector Machine, and XGBoost in classification performance and predictive capability.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.